Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer - Liu, G; Oettel, K; Ripple, G; Staab, M J; Horvath, D; Alberti, D; Arzoomanian, R; Marnocha, R; Bruskewitz, R; Mazess, R (Clin Cancer Res, 2002)